Speaker Profile
Biography
Kole T. Roybal is an associate professor in the Department of Microbiology and Immunology and Director of the PICI Center at the University of California, San Francisco and the Helen Diller Family Comprehensive Cancer Center and is an inaugural Chan Zuckerberg Biohub investigator. He is also the deputy director of the UCSF Center for Synthetic Immunology, which was recently funded by the Cancer Moonshot Initiative.The Roybal Lab harnesses the tools of synthetic biology and immunology to control and customize immune cell therapeutics for cancer and autoimmunity. Dr. Roybals body of work was foundational to the next-generation immune cell therapy company Cell Design Labs, where he was a founding scientist. Cell Design Labs was acquired by Gilead at the end of 2017. Dr. Roybal was also instrumental in developing universal CAR T-cell technology in collaboration with Xyphos Biosciences, which was acquired by Astellas at the end of 2019. He has now co-founded ArsenalBio, which focuses on building cellular therapies for solid tumors with a combination of cutting-edge synthetic biology and gene-editing technologies.In 2018 he received the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH Directors New Innovator Award.Dr. Roybal holds a PhD in immunology from The University of Texas Southwestern Medical Center at Dallas and was a Jane Coffin Childs Memorial Fund postdoctoral Fellow in the laboratory of Wendell A. Lim, PhD, at UCSF and the Howard Hughes Medical Institute.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Cindy Perettie, EVP Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
Fabian Gerlinghaus (Cellares)
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
Gudrun Stengel, Alida BioSciences




